On June 15, 2021 Patrys is pleased to report the publication of new data in the highly-regarded Journal of Clinical Investigation – Insight, demonstrating the ability of its PAT-DX1 antibody to cross the blood-brain barrier and inhibit the growth of brain cancers and metastases(Press release, Patrys, JUN 15, 2021, View Source [SID1234584035]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Most antibodies are unable to cross cell membranes or the blood-brain barrier, limiting their use in treating cancers of the brain. However, this latest research led by Dr James Hansen at Yale School of Medicine has shown the potential of Patrys’ unique deoxymab platform for tackling these difficult-to-reach-and-treat cancers.

Human glioblastoma cells were implanted in the brains of mice, which were then treated with PAT-DX1 once tumours had become established in the brain.